Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

Gnant, Michael; Mlineritsch, Brigitte; Schippinger, Walter; Luschin-Ebengreuth, G.; Pöstlberger, Sabine; Menzel, Christian; Jakesz, R.; Seifert, Michael; Hubalek, Michael; Bjelic‐Radisic, Vesna; Samonigg, Hellmut; Tausch, Christoph; Eidtmann, Holger; Steger, G.; Kwasny, Werner; Dubsky, Peter; Fridrik, Michael A.; Fitzal, Florian; Stierer, M.; Rücklinger, Ernst; Greil, Richard

doi:10.1056/nejmoa0806285

Cited by 948 publications

(610 citation statements)

References 49 publications

Supporting

Mentioning

568

Contrasting

Unclassified

Order By: Relevance

“…Of these trials, six were excluded since data regarding the osteonecrosis of the jaw could not be retrieved. Finally, 15 trials were included in the meta-analysis [7,8,10,17,[22][23][24][25][26][27][28][29][30][31][32].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis

Mauri

Valachis

Polyzos³

et al. 2009

Breast Cancer Res Treat

View full text Add to dashboard Cite

To estimate the cumulative randomized evidence for the overall incidence of bisphosphonates induced jaw osteonecrosis in adjuvant treatment of breast cancer. Systematic review and meta-analysis of randomized clinical trials. Trials were located through PubMed, ISI, Cochrane Library, and major cancer scientific meetings searches. We identified 15 studies reporting data on osteonecrosis of the jaw. A total of 10,694 randomized women were included, of whom 5,312 received bisphosphonates and 5,382 received either placebo or no treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

“…In addition, a recent clinical trial evidenced that use of zoledronic acid in adjuvant treatment of early breast cancer setting may prolong disease free survival when compared with non use [17].…”

Section: Introductionmentioning

confidence: 99%

Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis

Mauri

Valachis

Polyzos³

et al. 2009

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…The Austrian Breast and Colorectal Cancer Study Group (ABCSG)-12 trial showed that zoledronic acid not only counteracts effectively the demineralising effects from goserelin, but improves disease-free survival as well [2]. Accordingly, bone loss is manageable and should not restrict the use of goserelin.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, the optimal timing and duration of LHRH agonist treatment is yet to be defined [1][2][3][4]. Nevertheless, it is clear that ovarian ablation improves survival in premenopausal women with early breast cancer [3].…”

Section: Introductionmentioning

confidence: 99%

Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer

Sverrisdóttir

Johansson

et al. 2011

Breast Cancer Res Treat

View full text Add to dashboard Cite

Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer. Breast Cancer Research and Treatment, Springer Verlag, 2011, 128 (3) Abstract: Ovarian ablation improves survival in premenopausal early breast cancer, but the potential added value by luteinizing hormone-releasing hormone (LHRH) agonists to tamoxifen, is still not clear. The purpose of our study is to examine the efficacy of the LHRH agonist goserelin for adjuvant therapy of premenopausal breast cancer, the role of interaction between goserelin and tamoxifen, and the impact of estrogen receptor (ER) content. A total of 927 patients were included in the Stockholm part of the Zoladex in Premenopausal Patients (ZIPP) trial. They were randomly allocated in a 2 x 2 factorial study design to goserelin, tamoxifen, the combination of goserelin and tamoxifen or no endocrine therapy for 2 years, with or without chemotherapy. This is formally not a preplanned subset analysis presenting the endpoint first event. In this Stockholm sub-study, at a median follow up of 12.3 years, goserelin reduced the risk of first event by 32 % (P = 0.005) in the absence of tamoxifen, and tamoxifen reduced the risk by 27 % (P = 0.018) in the absence of goserelin. The combined goserelin and tamoxifen treatment reduced the risk by 24 % (P = 0.021) compared to no endocrine treatment. In highly ER positive tumours, there were 29% fewer events among goserelin treated (P = 0.044) and a trend towards greater risk reduction depending on the level of ER content. The greatest risk reduction from goserelin treatment was observed among those not receiving tamoxifen (HR: 0.52, P = 0.007). In conclusion, goserelin as well as tamoxifen, reduces the risk of recurrence in endocrine responsive premenopausal breast cancer. Women with strongly ER positive tumours may benefit more from goserelin treatment. The combination of goserelin and tamoxifen is not superior to either modality alone. With the limitations of a subset trial, these data have to be interpreted cautiously.

show abstract

“…Longterm problems from BP therapy are minimized because of the rather short courses of treatment that need to be used only during periods when the disease is active. Antiresorptive therapy has also been widely used in oncology for treatment of hypercalcemia and prevention of bone metastases [31].…”

Section: Antiresorptives In Diseases Other Than Osteoporosismentioning

confidence: 99%

The Effect of Antiresorptives on Bone Quality

Recker

Armas

2011

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background Currently, antiresorptive therapy in the treatment and prevention of osteoporosis includes bisphosphonates, estrogen replacement, selective estrogen receptor modulators (raloxifene), and denosumab (a human antibody that inactivates RANKL). The original paradigm driving the development of antiresorptive therapy was that inhibition of bone resorption would allow bone formation to continue and correct the defect. However, it is now clear increases in bone density account for little of the antifracture effect of these treatments. Questions/purposes We examined the antifracture benefit of antiresorptives deriving from bone quality changes. Methods We searched the archive of nearly 30,000 articles accumulated over more than 40 years in our research center library using a software program (Refman TM ). Approximately 250 publications were identified in locating the 69 cited here.

show abstract

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

Cited by 948 publications

References 49 publications

Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis

Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis

Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer

The Effect of Antiresorptives on Bone Quality

Contact Info

Product

Resources

About